HOME >> BIOLOGY >> NEWS
Extra-aggressive form of idiopathic pulmonary fibrosis identified

Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive lung disorder from which most patients die within 5 years after diagnosis. The disease is characterized by the insidious onset of dyspnea or cough and usually evolves slowly.

Now, Selman and coworkers present in an article published in the online, open-access journal PLoS ONE on Wednesday 30th May, strong evidence indicating that a subset of IPF patients has a short duration of symptoms before diagnosis and display an accelerated clinical course to end-stage disease. The authors postulate that these "rapid progressor" patients, predominantly smoking males, represent a distinct clinical phenotype compared with the usual "slow progressors" patients.

"These findings highlight the variability in the progression and outcome of IPF, and may explain, in part, the difficulty in obtaining significant and reproducible results in studies of therapeutic interventions in patients with IPF," said Dr Selman, who is the Director of Research at the National Institute of Respiratory Research in Mexico City and the lead author on this publication. "They also suggest that physicians should pay more attention to the time of onset of symptoms, and to look for other signs that allow the identification of these rapid progressor patients".

In this study the authors performed global gene expression analysis and other molecular studies in a subset of patients and identified a number of genes that were differentially expressed in both groups, suggesting that rapid progressors are biologically distinct from slow progressors.

"While preliminary, these results may allow investigators to identify biomarkers of disease progression," said Dr King, who is the Chief of Medicine at San Francisco General Hospital and an internationally renowned expert in research and management of pulmonary fibrosis.

The senior author on this paper, Dr Naftali Kaminski, who is the Director
'"/>

Contact: Moiss Selman
mselmanl@yahoo.com.mx
Public Library of Science
29-May-2007


Page: 1 2

Related biology news :

1. Gene expression patterns predict rapid decline in idiopathic pulmonary fibrosis patients
2. A candidate gene for familial idiopathic pulmonary fibrosis identified
3. New approach to pulmonary hypertension shows promise
4. Nitric oxide: Key to cardiovascular and pulmonary function and drug effectiveness
5. NIH gives PITT $13 million grant for chronic obstructive pulmonary disease research
6. Scientific meeting on pulmonary hypertension, December 7-8
7. Leveling the field for babies with persistent pulmonary hypertension
8. U-M scientists target key cells and signals that trigger pulmonary fibrosis
9. First different black/white mechanism in pulmonary fibrosis/scleroderma identified
10. Against pulmonary fibrosis
11. First report of cancer drug Gleevec as new target therapy for pulmonary hypertension

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/16/2016)... --  EyeLock LLC , a market leader of iris-based ... IoT Center of Excellence in Austin, Texas ... embedded iris biometric applications. EyeLock,s iris authentication ... with unmatched biometric accuracy, making it the most proven ... platform uses video technology to deliver a fast and ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... subsidiary of Infosys (NYSE: INFY ), and Samsung ... global partnership that will provide end customers with a ... and payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ... for financial services, but it also plays a fundamental part ...
(Date:4/19/2016)... , UAE, April 20, 2016 ... implemented as a compact web-based "all-in-one" system solution for ... biometric fingerprint reader or the door interface with integration ... modern access control systems. The minimal dimensions of the ... readers into the building installations offer considerable freedom of ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... , June 23, 2016   EpiBiome , a ... $1 million in debt financing from Silicon Valley Bank ... automation and to advance its drug development efforts, as ... facility. "SVB has been an incredible strategic ... services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... ... , ... In a new case report published today in STEM CELLS Translational ... lymphedema after being treated for breast cancer benefitted from an injection of stem cells ... this debilitating, frequent side effect of cancer treatment. , Lymphedema refers to ...
(Date:6/23/2016)... LONDON , June 23, 2016 ... & Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... Review , the peer-reviewed journal from touchONCOLOGY, ... the escalating cost of cancer care is placing ... a result of expensive biologic therapies. With the ...
(Date:6/23/2016)... ... 23, 2016 , ... Regulatory Compliance Associates® Inc. (RCA), a ... webinar on Performing Quality Investigations: Getting to Root Cause. This ... charge. , Incomplete investigations are still a major concern to the Regulatory Authorities ...
Breaking Biology Technology:
Cached News: